Histone deacetylase inhibition affects sodium iodide symporter expression and induces 131I cytotoxicity in anaplastic thyroid cancer cells

Thyroid

Volumn 23, Issue 7, 2013, Pages 838-846

  Pugliese, Mariateresa ^a   Fortunati, Nicoletta ^b   Germano, Antonina ^a   Asioli, Sofia ^a   Marano, Francesca ^a   Palestini, Nicola ^c   Frairia, Roberto ^a   Boccuzzi, Giuseppe ^a,b   Catalano, Maria Graziella ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE; IODINE 125; IODINE 131; LUCIFERASE; PANOBINOSTAT; SODIUM IODIDE SYMPORTER;

ANAPLASTIC THYROID CANCER; ARTICLE; CANCER CELL; CELL DIFFERENTIATION; CELL VIABILITY; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ASSAY; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; PRIMARY CELL CULTURE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION;

AGED; AGED, 80 AND OVER; ANIMALS; CELL LINE, TUMOR; FEMALE; HETEROGRAFTS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INDOLES; IODINE RADIOISOTOPES; MALE; MICE; MIDDLE AGED; NEOPLASM TRANSPLANTATION; SYMPORTERS; THYROID NEOPLASMS;

EID: 84881397890     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2012.0359     Document Type: Article

References (31)

1. Fassnacht M, Kreissl, MC, Weismann D, Allolio B 2009 New targets and therapeutic approaches for endocrine malignancies. Pharmacol Ther 123:117-141
2. Nagaiah G, Hossain A, Mooney CJ, Parmentier J, Remick SC 2011 Anaplastic thyroid cancer: A review of epidemiology, pathogenesis, and treatment. J Oncol 2011:542358-542371
3. Feinberg AP, Ohlsson R, Henikoff S 2006 The epigenetic progenitor origin of human cancer. Nat Rev Genet 7:21-33
4. Thaler F, Minucci S 2011 Next generation histone deacetylase inhibitors: The answer to the search for optimized epigenetic therapies? Expert Opin Drug Disc 6:393-404
5. Smith VE, Read ML, Turnell AS, Watkins RJ, Watkinson JC, Lewy GD, Fong JC, James SR, Eggo MC, Boelaert K, Franklyn JA, McCabe CJ 2009A novel mechanism of sodium iodide symporter repression in differentiated thyroid cancer J Cell Sci 122:3393-3402
6. Kogai T, Taki K, Brent GA 2006 Enhancement of sodium/ iodide symporter expression in thyroid and breast cancer. Endocr Relat Cancer 13:797-826
7. Sherman SI 2010 Targeted therapy of thyroid cancer. Biochem Pharmacol 80:592-601
8. Zarnegar R, Brunaud L, Kanauchi H, Wong M, Fung M, Ginzinger D, Duh QY, Clark OH 2002 Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor. Surgery 132:984-990
9. Fortunati N, Catalano MG, Arena K, Brignardello E, Piovesan A, Boccuzzi G 2004 Valproic acid induces the expression of the Na+ /I- symporter and iodine uptake in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab 89:1006-1009
10. Puppin C, D'Aurizio F, D'Elia AV, Cesaratto L, Tell G, Russo D, Filetti S, Ferretti E, Tosi E, Mattei T, Pianta A, Pellizzari L, Damante G 2005 Effects of histone acetylation on sodium iodide symporter promoter and expression of thyroidspecific transcription factors. Endocrinology 146:3967-3974
11. Fortunati N, Catalano MG, Marano F, Mugoni V, Pugliese M, Bosco O, Mainini F, Boccuzzi G 2010 The pan-DAC inhibitor LBH589 is a multi-functional agent in breast cancer cells: Cytotoxic drug and inducer of sodium-iodide symporter (NIS). Breast Cancer Res Treat 124:667-675
12. Oki Y, Copeland A, Younes A 2011 Clinical development of panobinostat in classical Hodgkin's lymphoma. Expert Rev Hematol 4:245-52
13. Catalano MG, Pugliese M, Gargantini E, Grange C, Bussolati B, Asioli S, Bosco O, Poli R, Compagnone A, Bandino A, Mainini F, Fortunati N, Boccuzzi G 2012 Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo. Int J Cancer 130:694-704
14. Catalano MG, Fortunati N, Pugliese M, Marano F, Ortoleva L, Poli R, Asioli S, Bandino A, Palestini N, Grange C, Bussolati B, Boccuzzi G 2012 Histone deacetylase inhibition modulates E-cadherin expression and suppresses migration and invasion of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 97:E1150-1159
15. Behr M, Schmitt TL, Espinoza CR, Loos U 1998 Cloning of a functional promoter of the human sodium/iodide-symporter gene. Biochem J 331:359-363
16. Elisei R, Vivaldi A, Ciampi R, Faviana P, Basolo F, Santini F, Traino C, Pacini F, Pinchera A 2006 Treatment with drugs able to reduce iodine efflux significantly increases the intracellular retention time in thyroid cancer cells stably transfected with sodium iodide symporter complementary deoxyribonucleic acid. J Clin Endocrinol Metab 91:2389- 2395
17. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C 2006 Clonogenic assay of cells in vitro. Nat Protoc 1:2315- 2319
18. Kondo T, Nakazawa T, Ma D, Niu D, Mochizuki K, Kawasaki T, Nakamura N, Yamane T, Kobayashi M, Katoh R 2009 Epigenetic silencing of TTF-1/NKX2-1 through DNA hypermethylation and histone H3 modulation in thyroid carcinomas. Lab Invest 89:791-799
19. Russo D, Damante G, Puxeddu E, Durante C, Filetti S 2011 Epigenetics of thyroid cancer and novel therapeutic targets. J Mol Endocrinol 46:R73-81
20. Puppin C, Passon N, Lavarone E, Di Loreto C, Frasca F, Vella V, Vigneri R, Damante G 2011 Levels of histone acetylation in thyroid tumors. Biochem Biophys Res Commun 411:679-683
21. Akagi T, Luong QT, Gui D, Said J, Selektar J, Yung A, Bunce CM, Braunstein GD, Koeffler HP 2008 Induction of sodium iodide symporter gene and molecular characterisation of HNF3 beta/FoxA2, TTF-1 and C/EBP beta in thyroid cells. Br J Cancer 99:781-788
22. Furuya F, Shimura H, Suzuki H, Taki K, Ohta K, Haraguchi K, Onaya T, Endo T, Kobayashi T 2004 Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin. Endocrinology 145:2865-2875
23. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, Haugen BR 2008 Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redun- dancy and misidentification. J Clin Endocrinol Metab 93:4331-4341
24. Vivaldi A, Miasaki FY, Ciampi R, Agate L, Collecchi P, Capodanno A, Pinchera A, Elisei R 2009 Re-differentiation of thyroid carcinoma cell lines treated with 5-aza-2¢- deoxycytidine and retinoic acid. Mol Cell Endocrinol 307:142-148
25. Kondo T, Asa SL, Ezzat S 2008 Epigenetic dysregulation in thyroid neoplasia. Endocrinol Metab Clin North Am 37:389- 400
26. Xing M 2007 Gene methylation in thyroid tumorigenesis. Endocrinology 148:948-953
27. Yoshida A, Taniguchi S, Hisatome I, Royaux IE, Green ED, Kohn LD, Suzuki K 2002 Pendrin is an iodide-specific apical porter responsible for iodide efflux from thyroid cells. J Clin Endocrinol Metab 87:3356-3361
28. Dingli D, Bergert ER, Bajzer Z, O'Connor MK, Russell SJ, Morris JC 2004 Dynamic iodide trapping by tumor cells expressing the thyroidal sodium iodide symporter. Biochem Biophys Res Commun 325:157-166
29. Wiseman SM, Griffith OL, Gown A, Walker B, Jones SJ 2011 Immunophenotyping of thyroid tumors identifies molecular markers altered during transformation of differentiated into anaplastic carcinoma. Am J Surg 201:580-586
30. Pilli T, Prasad KV, Jayarama S, Pacini F, Prabhakar BS 2009 Potential utility and limitations of thyroid cancer cell lines as models for studying thyroid cancer. Thyroid 19:1333- 1342
31. Verburg FA, Brans B, Mottaghy F 2011 Molecular nuclear therapies for thyroid carcinoma. Methods 55:230-237